PD-1 immune checkpoint blockade (ICB) can reinvigorate CD8+ exhausted T cells (Tex), potentiate effector function, and enhance tumor control, but most patients fail to achieve long-lasting clinical response (2). This evidence concerns the gene PDCD1 and neoplasm.